ArticleJournal of tropical medicine2022
Incidence and Temporal Trend of Antituberculosis Drug-Induced Liver Injury: A Systematic Review and Meta-Analysis.
Article in Journal of tropical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence.International journal of clinical pharmacy · 2025Pooled it
- Incidence and risk factors of antituberculosis drug-induced liver injury in India: A systematic review and meta-analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Pooled it
- Feasibility of tuberculosis drug-induced liver injury screening under programme settings in Southern India.Public health action · 2026Article
- Anti-tuberculosis drug-induced hepatotoxicity in people living with HIV.Asian biomedicine : research, reviews and news · 2026Article
- Anti-tuberculosis drug-induced hepatotoxicity among patients undergoing tuberculosis treatment at the Antituberculosis Center of Brazzaville, Republic of Congo.IJID regions · 2026Article
- CYP2E1 and CYP2D6 in Anti-Tuberculosis Drug-Induced Liver Injury: Mechanisms, Epigenetic Regulation, and Translational Implications.Clinical and translational science · 2026Review
- Incidence, risk factors, and outcomes of anti-tuberculosis drug-induced hepatotoxicity in people with and without HIV in Thailand and the Philippines.Asian biomedicine : research, reviews and news · 2026Article
- Anti-Tubercular Drug-Induced Liver Injury: Current Understanding and Emerging Directions.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in Thailand.Frontiers in public health · 2026Article
- Drug-induced liver injury as a strong independent predictor of in-hospital mortality in tuberculous meningitis: potential age-related effect modification suggested in a large lifespan cohort.Frontiers in medicine · 2026Article
- Diagnosis, Management, and Outcome of Antituberculous Drug-Induced Liver Injury in a Low-Resource Setting: A Case Report.Case reports in infectious diseases · 2026Article
- Adverse drug reactions, particularly liver disorders, drive interruptions in anti-tuberculosis treatment: A retrospective cohort study.British journal of clinical pharmacology · 2025Article
- Pharmacogenomic heterogeneity ofAnnals of medicine · 2025Observational
- Incidence and associated risk factors of anti-tuberculosis drug induced liver injury among TB patients.BMC infectious diseases · 2025Article
- Acute liver failure from anti-tuberculosis drug-induced liver injury: An update.World journal of hepatology · 2025Review
- Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka.BMC infectious diseases · 2025Article
- Drug-induced liver injury due to first-line antituberculosis medications in India: A major hindrance to achieve the goal of tuberculosis elimination.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Unraveling the Role of CYP2E1 in Antitubercular Drug-Induced Hepatotoxicity: From Molecular Mechanisms to Clinical Implications.International journal of hepatology · 2025Review
- Clinical Features of Anti-Tuberculosis Drug-Induced Liver Injury and Risk Factors for Severe Cases: A Retrospective Study in China.Infection and drug resistance · 2025Article
- Research on the treatment of rifampin-susceptible tuberculosis-Time for a new approach.PLoS medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards were followed, and the protocol was registered in PROSPERO (CRD42020200077). Five electronic databases were searched to identify eligible studies published between 1990 and 2022. Search terms included anti-TB treatment and drug-induced liver injury. Studies that reported the incidence of ATLI or provided sufficient data to calculate the incidence of ATLI were included, and duplicate studies were excluded. Meta-analysis was conducted on the basis of logit-transformed metrics for the incidence of ATLI with 95% confidence intervals (CIs), followed by a predefined subgroup meta-analysis. Temporal trend analyses were performed to describe the change in pooled incidence over time. A random effects metaregression was conducted to explore the source of heterogeneity. All statistical analyses were carried out using Results: A total of 160 studies from 156 records with 116147 patients were included in the meta-analysis. Based on the random effects model, the pooled incidence of ATLI was 11.50% (95% CI: 10.10%-12.97%) and showed an upward trend over time ( Conclusions: The present systematic review provided a basis for estimating the incidence of ATLI worldwide, which varied among patients with different anti-TB regimens in different geographical regions and with different coinfections and had an upward trend. Regular liver function monitoring is imperative for patient safety during the anti-TB treatment course.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.